Fiduciary Family Office LLC Buys Shares of 3,907 The Clorox Company (NYSE:CLX)

Fiduciary Family Office LLC bought a new position in shares of The Clorox Company (NYSE:CLX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,907 shares of the company’s stock, valued at approximately $636,000.

Other hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Clorox by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 15,277,580 shares of the company’s stock worth $2,339,150,000 after purchasing an additional 48,632 shares during the period. Nuance Investments LLC lifted its stake in shares of Clorox by 150.6% in the second quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock valued at $218,035,000 after purchasing an additional 960,094 shares during the period. Van ECK Associates Corp lifted its stake in shares of Clorox by 2.2% in the third quarter. Van ECK Associates Corp now owns 1,492,717 shares of the company’s stock valued at $237,372,000 after purchasing an additional 31,510 shares during the period. Bank of New York Mellon Corp increased its holdings in Clorox by 14.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 961,387 shares of the company’s stock valued at $131,200,000 after acquiring an additional 120,716 shares in the last quarter. Finally, Acadian Asset Management LLC increased its holdings in Clorox by 26.5% during the 1st quarter. Acadian Asset Management LLC now owns 882,526 shares of the company’s stock valued at $135,099,000 after acquiring an additional 184,847 shares in the last quarter. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Price Performance

CLX stock traded down $0.46 during trading on Tuesday, hitting $162.02. The company had a trading volume of 210,477 shares, compared to its average volume of 1,238,969. The firm has a market capitalization of $20.05 billion, a price-to-earnings ratio of 56.61, a P/E/G ratio of 3.11 and a beta of 0.41. The business has a 50 day moving average of $161.63 and a 200 day moving average of $146.33. The Clorox Company has a fifty-two week low of $125.46 and a fifty-two week high of $169.09. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.50. Clorox had a net margin of 4.78% and a return on equity of 316.08%. The company had revenue of $1.76 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same quarter last year, the firm posted $0.49 EPS. The business’s revenue for the quarter was up 27.0% on a year-over-year basis. As a group, research analysts predict that The Clorox Company will post 6.81 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd will be issued a $1.22 dividend. This represents a $4.88 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Wednesday, October 23rd. Clorox’s payout ratio is 170.03%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of Clorox from $144.00 to $151.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Barclays lifted their price target on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a research report on Friday. BNP Paribas raised shares of Clorox to a “strong sell” rating in a research report on Friday, September 6th. Evercore ISI reduced their target price on shares of Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research report on Monday, October 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Clorox from $148.00 to $174.00 and gave the stock a “neutral” rating in a research report on Friday, October 11th. Six analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $151.57.

Insiders Place Their Bets

In other Clorox news, EVP Angela C. Hilt sold 1,733 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the completion of the transaction, the executive vice president now directly owns 13,471 shares in the company, valued at $2,229,719.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.57% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.